Abstract
Administrating DSM through hepatic artery causes blood stasis for about one hour. DSM induces drug uptake in the tumor area, and moreover, DSM increases tumor-to-normal drug concentration ratio in the liver. Because of these characteristics, DSM has gotten the insurance adaptation for the local treatment of metastatic liver cancer in Japan.
We have treated various hepatic malignancies with transcatheter arterial chemoembolization using DSM(DSM-TACE). Response rate for liver metastasis of gastric cancer, liver metastasis of neuroendocrine carcinoma and liver metastasis and inoperable intrahepatic cholangiocarcinoma were 62.5%, 70.0% and 52.9%, respectively. Median survival times(MSTs) were 36.1 months, 28.4 months and 15.4 months, respectively. And MSTs of inoperable stage IV HCC was 23.0 months for responder and 5.8 months for non-responder, respectively. There was no liver injury related death.
In conclusion, DSM-TACE was found to be a relatively safe and effective treatment for inoperable hepatic malignancies.
